Kamran Alimoghaddam

Tehran University of Medical Sciences Iran

Kamran Alimoghaddam, M.D. was born in 1964 in Tehran (Iran), and his primary research field is in hematology, oncology and bone marrow transplantation. His past positions include: Internship at Hamadan University of Medical sciences, Hamadan (1990-1992); Residency of Internal Medicine at Tehran University of Medical Sciences (1992-1995); Fellowship of Hematology, Oncology and BMT, Tehran University of Medical Sciences (1996-1999); Assistant Professor of Medicine, Tehran University of Medical Sciences (1999-2005); and Associated Professor of Medicine, Tehran University of Medical Sciences (2005-2012). From 2012, Dr. Alimoghaddam is Professor of Medicine, at Tehran University of Medical Sciences. He is a member of EBMT, ESMO, EHA, ASCO, ASH, ECAR, Iranian society of Hematology/Oncology and Iranian society of Bone Marrow Transplantation. Dr. Alimoghaddam is also co-editor of International Journal of Hematology, Oncology and BMT and serves as a member for several editorial boards journals (Hematology, Oncology and Stem Cell Therapy Journal; Khoon (blood) journal; Cell Journal (Yakhteh)).

Kamran Alimoghaddam

1books edited

Latest work with IntechOpen by Kamran Alimoghaddam

Stem cells have a prominent role in normal life and also in pathogenesis of disorders. Today, these cells are clinically applicable in hematopoietic stem cell transplantation but expansion of their application in many more disorders needs more work. For safe and effective application of these cells, we need better knowledge of their biology, their interaction with other cells (especially supporting niche cells), growth, maturation and also immigration of stem cells through body in normal and abnormal conditions. Also for clinical application we need to understand better, their separation methods and safe manipulation. This book is written to clarify some aspects of stem cell biology, their characteristics, assessment of damage to cells during ex vivo manipulation and also their role in a model of cancers (chronic myeloid leukemia).

Go to the book